Share on LinkedInShare on LinkedIn

ARTICLE · 16 JULY 2026

Antitrust & Competition Life Sciences 1H 2026 Update

The first half of 2026 brought significant M&A activity and regulatory developments in life sciences, with the FTC returning to traditional antitrust enforcement principles. While this shift has added predictability to the regulatory landscape, practitioners must remain vigilant as agencies continue to scrutinize problematic transactions, particularly those involving emerging therapeutic areas or novel competitive dynamics.

United StatesAntitrust/Competition Law

The first half of 2026 featured a slew of significant M&A activity, regulatory developments abroad, and important jury verdicts in the life sciences space. As industry participants consider their next moves, it remains imperative to keep a close eye on the FTC in particular. The return of traditional antitrust enforcement principles has added a degree of predictability, but practitioners must still prepare for vigorous engagement on problematic transactions and those presenting novel issues or involving emerging therapeutic areas. 

Evolving Universe of Biopharma Acquirers

Big Pharma is not the only player using mergers and acquisitions to grow in the biopharmaceutical sector. In recent years, the sector has increasingly seen small and mid-sized pharmaceutical companies use M&A to support their long-term growth. Faced with many of the same strategic pressures as large pharmaceutical companies — including looming patent expirations and the need to strengthen pipelines — these

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from